Skip to main content
Clinical Trials/NCT04808401
NCT04808401
Recruiting
Not Applicable

Influence of Different Inspired Oxygen Fractions on Perioperative Myocardial Biomarkers, Myocardial Strain and Outcome in Patients Undergoing General Anaesthesia for Elective Non-cardiac Surgery: A Prospective Randomized Open-label Single Centre Pilot Study

Insel Gruppe AG, University Hospital Bern1 site in 1 country110 target enrollmentMay 7, 2021

Overview

Phase
Not Applicable
Intervention
Oxygen
Conditions
Coronary Artery Disease
Sponsor
Insel Gruppe AG, University Hospital Bern
Enrollment
110
Locations
1
Primary Endpoint
Difference in hsTnT from preoperative baseline
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The purpose of this study is to investigate the impact of supraphysiologic oxygen (hyperoxia) on myocardial function in anaesthetized patients undergoing non-cardiac vascular surgery.

Detailed Description

Up to 110 patients with either proven coronary artery disease (CAD) or two or more risk factors for CAD undergoing elective or non-emergent non-cardiac vascular surgery will be recruited. Three blood samples for levels of myocardial biomarkers will be obtained at different perioperative time points (before anaesthesia induction, 2 hours after skin closure and 24 hours after the end of the surgery). The three myocardial biomarkers investigated are high-sensitive Troponin T (hsTnT), N-terminal (NT)-pro hormone BNP (NT-proBNP) and heart-type fatty acid binding protein (H-FABP). In the timeframe shortly after the induction of anaesthesia and prior to the start of surgery, myocardial strain as a marker of cardiac function will be measured by transesophageal echocardiography (TEE). Echocardiography measurements will be acquired at two different oxygen states for each patient.The fraction of inspired oxygen (FiO2) will be adjusted to reach a normoxaemic state (FiO2=0.3) and a hyperoxic state (FiO2=0.8). Patients will be randomized to which oxygen level is investigated first. Thereafter, the patients are again randomly assigned to either the normoxaemic or the hyperoxic state for the remainder of the perioperative treatment until 2 hours after skin closure. Surgery will be performed as planned by the treating team. Differences in the perioperative levels of myocardial biomarkers at the different time points and their dynamics will be assessed. Echocardiography images will be analyzed in a blinded manner for cardiac function and systolic and diastolic strain parameters. The results will help anaesthesiologists to better weigh risks and benefits when selecting an inspired oxygen fraction in such patients, and will help to evaluate hyperoxia as a risk factor for myocardial injury.

Registry
clinicaltrials.gov
Start Date
May 7, 2021
End Date
December 2028
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Written informed consent
  • Patients eligible for the study should be scheduled for elective or non-emergent non-cardiac vascular surgery under general anaesthesia with endotracheal intubation, and have either
  • proven CAD and will undergo high- or intermediate surgical risk procedure according to European (European Society of Cardiology, ESC / European Society of Anaesthesiology and Intensive Care, ESAIC) guidelines on non-cardiac surgery.
  • two or more risk factors for CAD and will undergo high- or intermediate surgical risk procedures according to European ESC/ESAIC guidelines on non-cardiac surgery.

Exclusion Criteria

  • Acute coronary event 30 days before surgery
  • Acute congestive heart failure
  • Hemodynamic instability before induction of aneasthesia (vasopressor or inotrope infusion since hospitalization for index surgery)
  • Atrial fibrillation or other severe arrhythmia
  • Severe pulmonary disease (dependent on oxygen therapy or the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 4 or severe carbon monoxide diffusion impairment or severe pulmonary hypertension)
  • Preoperative oxygen saturation (SpO2) below 90% on room air
  • Increased risk of oxygen toxicity (e.g., chemotherapy for malignancy within 3 months, bleomycin treatment, airway laser surgery)
  • Scheduled surgery in the thoracic cavity
  • ICU admission for respirator weaning and delayed extubation
  • Pre-existing surgical site infection (SSI)

Arms & Interventions

Normoxaemia First + Hyperoxia Procedure

Patients will undergo TEE imaging at normoxaemia (FiO2=0.3) first, and hyperoxia (FiO2=0.8) will be targeted second. After the image acquisition patients receive hyperoxic concentrations.

Intervention: Oxygen

Normoxaemia First + Normoxia Procedure

Patients will undergo TEE imaging at normoxaemia (FiO2=0.3) first, and hyperoxia (FiO2=0.8) will be targeted second. After the image acquisition patients receive normoxic concentrations.

Intervention: Oxygen

Hyperoxia First + Hyperoxia Procedure

Patients will undergo TEE imaging at hyperoxia (FiO2=0.8) first, and normoxaemia (FiO2=0.3) will be targeted second. After the image acquisition patients receive hyperoxic concentrations.

Intervention: Oxygen

Hyperoxia First + Normoxaemia Procedure

Patients will undergo TEE imaging at hyperoxia (FiO2=0.8) first, and normoxaemia (FiO2=0.3) will be targeted second. After the image acquisition patients receive normoxic concentrations.

Intervention: Oxygen

Outcomes

Primary Outcomes

Difference in hsTnT from preoperative baseline

Time Frame: at 24 hours after surgery

ng/L

Secondary Outcomes

  • Difference in high sensitive TnT from preoperative baseline(at 2 hours after surgery)
  • Incidence of myocardial injury in non-cardiac surgery (MINS)(at 24 hours after surgery)
  • Difference in myocardial strain rate ratio between oxygen levels(Through study completion, within 1hour post-induction)
  • Differences in heart type fatty acid binding protein (H-FABP) from preoperative baseline(at 2 hours and 24 hours after surgery)
  • Difference in myocardial velocities between oxygen levels(Through study completion, within 1hour post-induction)
  • Difference in ejection fraction (EF)(Through study completion, within 1hour post-induction)
  • Difference in chamber volumes(Through study completion, within 1hour post-induction)
  • Difference in myocardial time to peak strain between oxygen levels(Through study completion, within 1hour post-induction)
  • Differences in N-terminal pro B-type natriuretic peptide (NT-proBNP) from preoperative baseline(at 2 hours and 24 hours after surgery)
  • Difference in peak torsion(Through study completion, within 1hour post-induction)
  • Difference in myocardial strain rate between oxygen levels(Through study completion, within 1hour post-induction)
  • Difference in myocardial displacement between oxygen levels(Through study completion, within 1hour post-induction)
  • Difference in myocardial time to peak displacement between oxygen levels(Through study completion, within 1hour post-induction)
  • Difference in peak twist(Through study completion, within 1hour post-induction)
  • Difference in myocardial velocity ratio between oxygen levels(Through study completion, within 1hour post-induction)

Study Sites (1)

Loading locations...

Similar Trials